GALVANIZE
Galvanize , the leader in SaaS governance, risk, and compliance (GRC) software, is pleased to announce that it has been named a Leader in The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020.
Galvanize received the top scores possible in the risk and control management, document management, audit management, and IT risk management criteria. In addition, the company was among the top ranked in the criteria of advanced predictive analytics, which is defined as “superior capabilities relative to others in the evaluation, including AI and ML capability to support advanced modelling in Python and R, advanced anomaly detection, and continuous auditing.”
“We’re extremely proud to be named as a Leader in Forrester’s rigorous evaluation system,” said Dan Zitting, chief product & strategy officer, Galvanize. “We believe this accomplishment is a testament to the hard work of marrying our GRC platforms to create an end-to-end system that sets the industry standard for stronger IT security, risk management, compliance, and assurance.”
The report notes the company’s successful integration of ACL and Rsam to create a combined industry catalyst. According to the report, the HighBond platform, which has achieved FedRAMP Moderate authorization, “combines Rsam’s aptitude for collecting and operationalizing data with ACL’s powerful analytics and robotic process automation, enabling GRC pros to capitalize on digital transformation”. The report explains: “Notwithstanding the sophistication, customers enjoy managing the platform themselves and appreciate Client Partners, the vendor’s unique take on customer success that combines guidance, best practices, and access to other customers to help solve similar problems.”
“We’re witnessing a shift among the world’s most influential businesses, as they demand value from organizations that stretch beyond financial profit,” said Laurie Schultz, president & CEO, Galvanize. “Being recognized as a Leader by Forrester is extremely impactful, as it corroborates our unique vision to create a comprehensive GRC offering worthy of tomorrow’s workforce, as well as bringing us closer to our goal of consolidating the GRC industry, and being the operating system for conscious organizations.”
The Forrester Wave™ is one of the industry’s most complete and detailed analyses, using a transparent methodology composed of vendor surveys, product demos, and customer reference calls to compare top players in the market. This latest recognition builds on a long history of industry recognition among leading analyst firms for Galvanize. The company was named a Leader in Gartner Magic Quadrant for IT Vendor Risk Management Tools in December 2019 and a Leader in Gartner Magic Quadrant for IT Risk Management in July 2019.
A full, complimentary version of the report, The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020 is available for download from Galvanize at: https://info.wegalvanize.com/forrester-wave-grc-platforms-2020-report.html
To learn more about Galvanize and its comprehensive GRC platform, visit: wegalvanize.com .
About Galvanize:
Galvanize builds award-winning, cloud-based security, risk management, compliance, and audit software to drive change in some of the world’s largest organizations. We’re on a mission to unite and strengthen individuals and entire organizations through the integrated HighBond software platform. With more than 6,300 customer organizations in 130 countries, Galvanize is connecting teams in many of the Fortune 1,000 and S&P 500 companies, and hundreds of government organizations, banks, manufacturers, and healthcare organizations. Whether these professionals are managing threats, assessing risk, measuring controls, monitoring compliance, or expanding assurance coverage, HighBond automates manual tasks, blends organization-wide data, and broadcasts it in easy-to-share dashboards and reports. But we don’t just make technology—we provide tools that inspire individuals to achieve great things and do heroic work in the process.
Supporting Resources:
Website: www.wegalvanize.com
Twitter: https://twitter.com/wegalvanize
LinkedIn: https://linkedin.com/company/wegalvanize
©2020 ACL Services Ltd. ACL, Galvanize, the Galvanize logo, HighBond, and the HighBond logo are trademarks or registered trademarks of ACL Services Ltd. dba Galvanize. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005234/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
